SLP logo

SLP
Simulations Plus Inc.

1,282
Mkt Cap
$300.46M
Volume
120,312.00
52W High
$35.02
52W Low
$11.09
PE Ratio
-4.76
SLP Fundamentals
Price
$14.16
Prev Close
$14.87
Open
$14.77
50D MA
$12.64
Beta
0.94
Avg. Volume
200,768.73
EPS (Annual)
-$3.22
P/B
2.25
Rev/Employee
$371,732.39
$253.09
Loading...
Loading...
News
all
press releases
Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised
CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from Brokerages
Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and t...
MarketBeat·2d ago
News Placeholder
Iridium's Q1 Earnings Miss Estimates, Revenues Increase Y/Y
IRDM misses Q1 2026 EPS estimates despite steady service revenue growth, as IoT demand and strategic investments shape its 2026 outlook.
Zacks·5d ago
News Placeholder
SAP's Q1 Earnings & Revenues Up Y/Y on Cloud Momentum & AI Tailwinds
SAP posts 20% EPS growth in Q1 2026 as cloud and AI momentum drive revenue gains, boosting shares despite macro uncertainty and signaling continued enterprise demand strength.
Zacks·5d ago
News Placeholder
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (Lonza), a leading contract development and...
Business Wire·8d ago
News Placeholder
Badger Meter's Q1 Earnings & Revenues Miss Estimates, Stock Dips
BMI misses Q1 estimates as sales fall 9% on project delays, but a strong pipeline and UDlive acquisition signal confidence in long-term growth.
Zacks·9d ago
News Placeholder
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand...
Business Wire·9d ago
News Placeholder
Insider Selling: Simulations Plus (NASDAQ:SLP) CRO Sells 1,000 Shares of Stock
Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) CRO John Anthony Dibella II sold 1,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $13.37, for a total transaction of $13,370.00. Following the transaction, the executive...
MarketBeat·12d ago
News Placeholder
John Anthony Dibella II Sells 1,000 Shares of Simulations Plus (NASDAQ:SLP) Stock
Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) CRO John Anthony Dibella II sold 1,000 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an...
MarketBeat·13d ago
News Placeholder
Simulations Plus Q2 Earnings Call Highlights
Simulations Plus (NASDAQ:SLP) reported second-quarter fiscal 2026 revenue of $24.3 million, exceeding the top-line guidance management provided last quarter, as the company delivered growth in both...
MarketBeat·16d ago
<
1
2
...
>

Latest SLP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.